Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

evaluation of Anastrozole therapy as adjuvant treatment in post.menopausal women with not advanced breast cancer únder naturalistic conditions

Outcome Time Frame:

12 months

Safety Issue:

No

Principal Investigator

H Brasch

Investigator Role:

Study Director

Investigator Affiliation:

AstraZeneca Germany

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

Ax-003

NCT ID:

NCT00638391

Start Date:

May 2005

Completion Date:

March 2007

Related Keywords:

• Breast Cancer
• Primary early MCa
• Arimidex
• Breast Neoplasms

Name	Location